TriangleDISEASE & TREATMENT SETTING
Pomalyst: multiple myeloma after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Broader topic: Multiple Myeloma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have d
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Pomalyst (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice